Bundibugyo Ebola Outbreak: No Vaccine, Rising Deaths, and a Race for Answers

In contrast, Uganda declared the end of its outbreak on 28 July 2026 after 42 days without a new locally transmitted case. The last imported case was discharged on 16 July . Uganda remains at risk of imported cases due to ongoing transmission in the neighboring DRC .

The Vaccine & Clinical Pipeline: A Race Against Time

There is no approved vaccine or therapeutic specifically for the Bundibugyo virus . Multiple candidates are now racing forward, representing a critical moment in the response.

1. Moderna — mRNA-1469 (Phase 1)

On 4 August 2026, Moderna announced the initiation of its first-in-human Phase 1 trial of mRNA-1469, an mRNA-based vaccine against Bundibugyo ebolavirus . The trial is being conducted at three sites in Canada under Health Canada authorization, with approximately 80 volunteers evaluating safety and immunogenicity . If successful, Moderna plans to rapidly initiate Phase 2 and 3 trials . The program is part of an expanded collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI), which has committed up to US$50 million to back the program .

2. University of Oxford — ChAdOx1 BDBV (Phase 1)

Oxford launched the world's first clinical trial of a Bundibugyo-specific vaccine (BD-Ebov) in July 2026, using the same ChAdOx1 viral-vector platform as the Oxford/AstraZeneca COVID-19 vaccine . The first volunteer was vaccinated on 24 July 2026 . The Phase 1 trial is evaluating safety and immune response in 50 healthy adults in Oxford, with plans to test in outbreak settings in Uganda later in 2026 . The Serum Institute of India has already manufactured and stockpiled approximately 620,000 doses of the experimental vaccine in anticipation of later-stage trials .

3. WHO Recommendation — Ervebo (rVSV-ZEBOV) Cross-Trial

On 31 July 2026, WHO's Technical Advisory Group (TAG-CVP) recommended that Ervebo — the only licensed Ebola vaccine, approved for Zaire ebolavirus — be prioritized for inclusion in a randomized clinical trial against Bundibugyo virus disease . New animal data suggest Ervebo offers some protection against BVD, particularly against death . Gavi welcomed the recommendation .

Key shift: WHO initially advised against using Ervebo for Bundibugyo due to insufficient cross-protection evidence , but after the 31 July TAG-CVP meeting, the DRC formally submitted an emergency stockpile request to the International Coordinating Group for Ervebo doses . This decision was driven in part by observational data showing that none of the 242 recorded deaths with available vaccination status involved a previously vaccinated individual .

4. CEPI — Parallel Manufacturing Commitment

CEPI has funded parallel manufacturing scale-up efforts for Moderna's mRNA-1469 to accelerate dose availability if efficacy is shown, building on Moderna's prior filovirus research . Similarly, Oxford's Oxford Vaccine Group is working with the Serum Institute of India to rapidly produce and scale doses of the ChAdOx1 BDBV vaccine, with manufacturing readiness running in parallel to Phase 1 trial results .

5. Moderna — Access Pricing Pledge

Moderna has committed to an access and pricing pledge for low- and middle-income countries as part of its CEPI partnership agreement, though specific price tiers have not been publicly detailed. The company has stated its intent to ensure affordable supply for LMICs if the vaccine proves effective .

Operational Challenges: A Crisis on Multiple Fronts

The response to the outbreak is severely hampered by compounding crises that go beyond the virus itself:

• Armed conflict: The outbreak epicenter in Ituri Province lies in an active conflict zone where armed group violence restricts access for surveillance, vaccination teams, and burial teams. Health facilities have been attacked, and responders face severe security constraints .
• Underfunding: The broader humanitarian response in the DRC, including the Ebola response, is critically underfunded. This limits the deployment of rapid response teams, contact tracing, and isolation capacity .
• Strained humanitarian aid operations: The convergence of the Ebola outbreak with existing humanitarian crises — displacement, food insecurity, and other disease outbreaks — has overwhelmed local health systems. The UN has reported a disproportionate rise in childhood deaths .